We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Committee Votes Down Janssen’s Plivensia Arthritis Drug, Citing Safety Concerns
FDA Committee Votes Down Janssen’s Plivensia Arthritis Drug, Citing Safety Concerns
An FDA advisory committee voted 12-to-1 against recommending approval of Janssen’s Plivensia (sirukumab) in treating rheumatoid arthritis, saying its safety profile raised too many concerns.